The mitochondrial β-oxidation enzyme HADHA restrains hepatic glucagon response by promoting β-hydroxybutyrate production

An Pan, Xiao-Meng Sun, Feng-Qing Huang, Jin-Feng Liu, Yuan-Yuan Cai, Xin Wu, Raphael N. Alolga, Ping Li, Bao-Lin Liu, Qun Liu () and Lian-Wen Qi ()
Additional contact information
An Pan: State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University
Xiao-Meng Sun: State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University
Feng-Qing Huang: State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University
Jin-Feng Liu: Clinical Metabolomics Center, China Pharmaceutical University
Yuan-Yuan Cai: State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University
Xin Wu: State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University
Raphael N. Alolga: Clinical Metabolomics Center, China Pharmaceutical University
Ping Li: State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University
Bao-Lin Liu: State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University
Qun Liu: State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University
Lian-Wen Qi: State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University

Nature Communications, 2022, vol. 13, issue 1, 1-13

Abstract: Abstract Disordered hepatic glucagon response contributes to hyperglycemia in diabetes. The regulators involved in glucagon response are less understood. This work aims to investigate the roles of mitochondrial β-oxidation enzyme HADHA and its downstream ketone bodies in hepatic glucagon response. Here we show that glucagon challenge impairs expression of HADHA. Liver-specific HADHA overexpression reversed hepatic gluconeogenesis in mice, while HADHA knockdown augmented glucagon response. Stable isotope tracing shows that HADHA promotes ketone body production via β-oxidation. The ketone body β-hydroxybutyrate (BHB) but not acetoacetate suppresses gluconeogenesis by selectively inhibiting HDAC7 activity via interaction with Glu543 site to facilitate FOXO1 nuclear exclusion. In HFD-fed mice, HADHA overexpression improved metabolic disorders, and these effects are abrogated by knockdown of BHB-producing enzyme. In conclusion, BHB is responsible for the inhibitory effect of HADHA on hepatic glucagon response, suggesting that HADHA activation or BHB elevation by pharmacological intervention hold promise in treating diabetes.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-28044-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-28044-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-28044-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().